$6.33
6.75% yesterday
Nasdaq, Nov 25, 10:00 pm CET
ISIN
KYG596651029
Symbol
MGTX
Sector
Industry

MeiraGTx Holdings plc Stock price

$6.33
+0.47 8.02% 1M
+1.05 19.77% 6M
-0.69 9.83% YTD
+1.22 23.87% 1Y
-12.55 66.47% 3Y
-11.14 63.77% 5Y
-8.67 57.80% 10Y
Nasdaq, Closing price Mon, Nov 25 2024
+0.40 6.75%
ISIN
KYG596651029
Symbol
MGTX
Sector
Industry

Key metrics

Market capitalization $494.71m
Enterprise Value $458.58m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 32.92
P/S ratio (TTM) P/S ratio 35.51
P/B ratio (TTM) P/B ratio 5.14
Revenue (TTM) Revenue $13.93m
EBIT (operating result TTM) EBIT $-176.48m
Free Cash Flow (TTM) Free Cash Flow $-102.53m
Cash position $122.87m
EPS (TTM) EPS $-1.31
P/E forward negative
P/S forward 38.05
EV/Sales forward 35.28
Short interest 2.97%
Show more

Is MeiraGTx Holdings plc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.

MeiraGTx Holdings plc Stock Analysis

Unlock Scores for Free

Analyst Opinions

5 Analysts have issued a MeiraGTx Holdings plc forecast:

5x Buy
100%

Analyst Opinions

5 Analysts have issued a MeiraGTx Holdings plc forecast:

Buy
100%

Financial data from MeiraGTx Holdings plc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
14 14
67% 67%
100%
- Direct Costs 26 26
209% 209%
184%
-12 -12
135% 135%
-84%
- Selling and Administrative Expenses 22 22
101% 101%
157%
- Research and Development Expense 129 129
66% 66%
927%
-163 -163
117% 117%
-1,169%
- Depreciation and Amortization 14 14
65% 65%
98%
EBIT (Operating Income) EBIT -176 -176
112% 112%
-1,267%
Net Profit -88 -88
21% 21%
-633%

In millions USD.

Don't miss a Thing! We will send you all news about MeiraGTx Holdings plc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

MeiraGTx Holdings plc Stock News

Positive
Seeking Alpha
about one month ago
MeiraGTx Holdings plc's GAD gene therapy for Parkinson's Disease shows promising phase 1/2 results, with significant improvements in UPDRS Part 3 and PDQ-39 scores. The company plans to discuss phase 3 study designs with regulatory agencies in Q4 2024, potentially initiating late-stage studies in 2025. MeiraGTx secured $50 million in funding, including a $30 million equity investment from Sanof...
Neutral
GlobeNewsWire
about 2 months ago
Results indicate a potent and effective locally delivered AAV-BDNF gene therapy for the treatment of obesity caused by MC4R deficiency Results indicate a potent and effective locally delivered AAV-BDNF gene therapy for the treatment of obesity caused by MC4R deficiency
Neutral
GlobeNewsWire
4 months ago
- Positive data from the Phase 1 AQUAx study in radiation-induced xerostomia (RIX) presented at the American Academy of Oral Medicine 2024 annual meeting (AAOM) showed meaningful improvements in patient-reported outcomes and saliva production with AAV2-hAQP1 treatment
More MeiraGTx Holdings plc News

Company Profile

MeiraGTx Holdings Plc is a clinical-stage biotech company, which engages in the development of novel gene therapy treatments. It operates through the United States and United Kingdom geographical segments. Its pipeline includes AAV-CNGB3, AAV-CNGA3, AAV-RPE65, AAV-RPGR, AAV-AQP1 and AAV-UPF1. The company was founded on March 20, 2015 and is headquartered in New York, NY.

Head office Cayman Islands
CEO Alexandria Forbes
Employees 425
Founded 2015
Website www.meiragtx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today